Drug intelligence / Profile preview

GCM-102

Development stage: Preclinical
Lead developer: Gencellmed
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies

Overview

GCM-102 is an HSV-1-based oncolytic virus developed by Gencellmed for the treatment of solid tumors. The therapeutic is engineered using Gencellmed's proprietary SMART (Synthetic & Multi-Antigen Retargeting Technology) platform, which is designed to enable the virus to selectively target and infect cancer cells while minimizing impact on healthy tissues. By utilizing a replication-competent herpes simplex virus type 1 (HSV-1) backbone, GCM-102 aims to induce direct oncolysis of tumor cells and stimulate a systemic anti-tumor immune response. The program is currently in the preclinical stage of development.

Beyond the preview

Go deeper on GCM-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GCM-102.

Explore the full profile